Semax

Research-Grade

Semax is a synthetic analog of the ACTH(4-10) fragment, designed by Russian researchers to retain cognitive-enhancing properties of the parent molecule while dropping the hypothalamic-pituitary-adrenal activation. It has been marketed in Russia since the late 1990s for stroke recovery, cognitive impairment, and ADHD-adjacent indications. Its most cited mechanism is upregulation of BDNF and nerve growth factor (NGF) in the hippocampus and prefrontal cortex, along with modulation of monoamine (dopamine, serotonin) turnover. Administration is intranasal; the peptide has poor oral bioavailability. N-Acetyl Semax Amidate (NA Semax) is a modified version with extended half-life. Western regulatory recognition is limited. Most clinical evidence comes from Russian-language publications and has not been independently replicated in Western trial settings.